Company profile
BOLT BIOTHERAPEUTICS, INC.
NASDAQ:BOLTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TRASTUZUMAB IMBOTOLIMOD | phase2 | — | 2 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06921837 | phase1_2 | recruiting | 2025-05-26 | 2027-05-01 | Bolt Biotherapeutics, Inc. | A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer |
| NCT04278144 | phase1_2 | terminated | 2020-02-24 | 2024-12-10 | Bolt Biotherapeutics, Inc. | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors |
| NCT06052852 | phase1 | terminated | 2023-10-11 | 2025-08-01 | Bolt Biotherapeutics, Inc. | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies |
| NCT05954143 | phase2 | terminated | 2023-11-30 | 2024-09-20 | Bolt Biotherapeutics, Inc. | Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer |
FDA applications (0)
No records yet.